home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  

registry of biomedical companies

  May 22, 2022
promoting the transfer of scientific know-how between industry and academia
Registry of biomedical companies:

[3] [7] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 452 active entries


3rd Floor, Serene Chambers, Rd#7, Banjara Hills

Phone: ++91-40-3548507/3543010/360884
Fax: ++91-40-3548476/3541713

Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.


Biotechnology for the preservation of life is a major concern and has been the single focus of our efforts in research, aimed at improving the quality of life. Developing India's first world class Hepatitis-B vaccine is the first step, and there are many more to follow. Proving once again that focused research is the key to a better and healthier life for the people of this world.

We at Shantha Biotechnics are committed to a single purpose: to achieve break throughs in modern biotechnology leading to development of products and services that address critical healthcare needs.

Giving strength to this mission is our state-of-the-art R&D facility, equipped with sophisticated instrumentation for industrial R&D in modern biotechnology. Our R & D is manned by highly qualified and experienced scientific personnel with experience in various facets of modern biology.

And our efforts have been rewarded. We have achieved pioneer status in developing and commercialising a recombinant DNA-based human healthcare product - the Hepatitis-B vaccine - in India. The near future may witness more achievements: major generics like Interferon Alpha (Shanferon), Insulin and Streptokinase; Therapeutic Antibodies for lung carcinoma, melanoma and cardiovascular diseases; Diagnostic Kits , new vaccines against Hepatitis-C and Hepatitis-E; a new generation vaccine against Hepatitis-B and other innovative biopharmaceuticals.
We have the competence to provide high quality contract R & D services ranging from molecular cloning to process development and formulation.

As we move closer to our goal of achievieng global presence in biotechnology, we continue our efforts to introduce innovations that will make way for a healthier world.

Last update of this entry: February 18, 2002

home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2022 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.